.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,250,419

« Back to Dashboard

Claims for Patent: 7,250,419

Title:Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
Inventor(s): Hardern; David (Sutton Bonington, GB), Ingall; Anthony (Loughborough, GB), Springthorpe; Brian (Loughborough, GB), Willis; Paul (West Bridgford, GB), Guile; Simon (Loughborough, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:11/230,493
Patent Claims: 1. A compound selected from the group consisting of [1S-(1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.)]-3-[7-[2-(3,4-difluoroph- enyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3- -yl)-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol, and pharmaceutically acceptable salts thereof.

2. The compound 1S-(1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.)]-3-[7-2-(3,4-difluorophen- yl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-y- l)-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol.

3. A pharmaceutical composition comprising a compound as claimed in claim 1 in combination with a pharmaceutically acceptable diluent, adjuvant and/or carrier.

4. A pharmaceutical composition comprising a compound as claimed in claim 2 in combination with a pharmaceutically acceptable diluent, adjuvant and/or carrier.

5. A method of treatment of myocardial infarction which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 1.

6. A method of treatment of myocardial infarction which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 2.

7. A method of treatment of thrombotic stroke which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 1.

8. A method of treatment of thrombotic stroke which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 2.

9. A method of treatment of transient ischaemic attacks which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 1.

10. A method of treatment of transient ischaemic attacks which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 2.

11. A method of treatment of stable and unstable angina which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 1.

12. A method of treatment of stable and unstable angina which comprises administering to a person suffering therefrom a therapeutically effective amount of a compound according to claim 2.

13. A method of inhibiting platelet aggregation in a person which comprises administering a therapeutically effective amount of a compound according to claim 1 to said person.

14. A method of inhibiting platelet aggregation in a person which comprises administering a therapeutically effective amount of a compound according to claim 2 to said person.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc